<DOC>
	<DOC>NCT02453282</DOC>
	<brief_summary>This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced or metastatic NSCLC</brief_summary>
	<brief_title>Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).</brief_title>
	<detailed_description>Patients will be randomized in a 1:1:1 ratio to receive treatment with MEDI4736 + tremelimumab combination therapy, MEDI4736 monotherapy, or Standard of Care (SoC) therapy.</detailed_description>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For inclusion in the study, patients should fulfill the following criteria: Aged at least 18 years Documented evidence of Stage IV NSCLC No sensitizing EGFR mutation or ALK rearrangement No prior chemotherapy or any other systemic therapy for recurrent/metastatic NSCLC World Health Organization (WHO) Performance Status of 0 or 1 Patients should not enter the study if any of the following exclusion criteria are fulfilled: 1. Mixed smallcell lung cancer and NSCLC histology, sarcomatoid variant 2. Brain metastases or spinal cord compression unless asymptomatic, treated and stable (not requiring steroids) 3. Prior exposure to Immunomodulatory therapy (IMT), including, but not limited to, other anticytotoxic Tlymphocyteassociated antigen 4 (CTLA4), antiprogrammed cell death1 (PD1), antiprogrammed cell death ligand 1 (PDL1), or anti PDL2 antibodies, excluding therapeutic anticancer vaccines 4. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>NSCLC, PD-L1, MEDI4736, Tremelimumab, PFS, OS</keyword>
</DOC>